Benjamin A Nacev

University of Pittsburgh
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (8)

Year:

2026

Year:

2026

Background Response to immune checkpoint inhibition (ICI) in sarcomas is overall low and heterogeneous. Understanding determinants of ICI outcomes may improve efficacy and patient selection. Thus, we investigated whether the expression of transposable elements (TEs), which are epigenetically silenced and can stimulate antitumor immunity, influence ICI outcomes and immune infiltrates in common sarcoma subtypes. Methods We used transcriptomic data to assign immune enhanced versus immune depleted status to 67 pretreatment and on-treatment biopsies of sarcomas from patients treated on ICI trials, along with additional cohorts from The Cancer Genome Atlas (TCGA) and an independent ICI trial (SARC028). A machine learning technique (lasso-penalized logistic regression) controlled for sarcoma subtype was used to determine if TE and epigenetic regulatory gene expression predict immune infiltrates. Correlations between top features in these models and sarcoma immune infiltrates, immune pathway expression, and clinical outcomes were explored. Results Expression of TEs and epigenetic regulators significantly predicted immune enhanced status. TE subfamilies and Ikaros family zinc finger 1 ( IKZF1 ), a chromatin-modulating transcription factor, were significantly contributory. TE and IKZF1 expression positively correlated with tumor immune infiltrates, inflammatory pathways, and improved clinical outcomes, and increased in tumors that gained immune infiltrates during ICI treatment. TE and IKZF1 expression similarly correlated with overall survival and immune features in a TCGA cohort. In an additional cohort of patients with sarcoma treated with ICI, IKZF1 expression correlated with progression-free survival and inflammatory features. Conclusions TE and IKZF1 expression warrant further translational investigation as potential biomarkers of tumor immune infiltrates and outcomes following ICI treatment, and as therapeutic targets in sarcomas.

Year:

2025

Background ATRX is a tumor suppressor and key regulator of transcriptionally repressive epigenetic states. We investigate the impact of ATRX loss on gene expression, DNA methylation, and transposable element (TE) expression in common soft tissue sarcoma tumors, a family of rare cancers. Methods Using data from The Cancer Genome Atlas (TCGA), we analyzed 234 tumors from patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS), soft tissue leiomyosarcoma (LMS), uterine LMS (uLMS), and myxofibrosarcoma (MFS). Corresponding clinical outcome and patient data, DNA sequencing, RNA sequencing, and 450K methylation data were integrated to assess ATRX-dependent features. Results ATRX loss was associated with significantly altered gene expression with the greatest impact in LMS/uLMS with 31 (33.0%) genes downregulated and 63 (66.0%) genes upregulated (FDR < 0.05), consistent with a role for ATRX in transcriptional silencing. Methylation profiling identified 269 differentially methylated CpGs (FDR<0.05), with a marked hypomethylation effect. ATRX loss was associated with loss of TE silencing with 97% (n=93) of differentially expressed TEs upregulated, indicating that ATRX loss contributes to a marked de-repression of TEs. The median overall survival in LMS patients was 81.0 vs 34.9 months for tumors with ATRX retention and loss (p log-rank =0.0023). Conclusions ATRX loss in sarcomas leads to DNA hypomethylation, increased expression of TEs, as well as transcriptional dysregulation affecting key oncogenic pathways. ATRX status may serve as a potential biomarker for prognosis and therapeutic stratification. Future clinical trials investigating epigenetic therapies could offer novel treatment strategies for ATRX-deficient sarcomas.

Year:

2025

PURPOSE We hypothesized that ACR-368 (prexasertib) would be active in desmoplastic small round cell tumor (DSRCT) because of favorable responses in preclinical models. METHODS Preclinical work identified ACR-368 activity in DSRCT, and a phase I/II trial of ACR-368 and irinotecan in patients 12 months and older with relapsed/refractory DSRCT was conducted. The primary objectives were determination of recommended phase II dose (RP2D) and best overall response rate (ORR) at the RP2D in DSRCT, with ≥3 of 16 responses considered promising. RESULTS Preclinical data confirmed ACR-368 as potentially therapeutic in DSRCT, and 19 patients were enrolled in a subsequent clinical trial. Treatment was well tolerated, and cytopenias were managed using growth factors. Fifteen of 19 patients, including five of six achieving PR, had previously received irinotecan. The estimated ORR at the RP2D was 23% (lower boundary one-sided 90% CI, 9%), exceeding the unpromising rate of 5%. In addition, three patients with DSRCT had a PR at doses other than the RP2D, bringing the ORR for all doses (n = 19) to 32% (90% CI, 15% to 53%). The median overall survival was 19 months (95% CI, 13 to 36). CONCLUSION The RP2D of ACR-368 with irinotecan by age group is ACR-368 105 or 150 mg/m 2 once on day 1 (>21 years or ≤21 years, respectively) and irinotecan 15 mg/m 2 once daily for 5 days in 21-day cycles for both groups. The study met its primary objective to consider ACR-368 and irinotecan promising in DSRCT and, to our knowledge, is the first incorporating a targeted therapy to achieve this magnitude of response.

Year:

2025

Purpose: Epacadostat, an indole 2,3 dioxygenase 1 (IDO1) inhibitor, proposed to shift the tumor microenvironment toward an immune-stimulated state, showed early promise in melanoma but has not been studied in sarcoma. This study combined epacadostat with pembrolizumab, which has modest activity in select sarcoma subtypes. Patients and Methods: This phase II study enrolled patients with advanced sarcoma into five cohorts including (i) undifferentiated pleomorphic sarcoma (UPS)/myxofibrosarcoma, (ii) liposarcoma (LPS), (iii) leiomyosarcoma (LMS), (iv) vascular sarcoma, including angiosarcoma and epithelioid hemangioendothelioma (EHE), and (v) other subtypes. Patients received epacadostat 100 mg twice daily plus pembrolizumab at 200 mg/dose every 3 weeks. The primary endpoint was best objective response rate (ORR), defined as complete response (CR) and partial response (PR), at 24 weeks by RECIST v.1.1. Results: Thirty patients were enrolled [60% male; median age 54 years (range, 24–78)]. The best ORR at 24 weeks was 3.3% [PR, n = 1 (leiomyosarcoma); two-sided 95% CI, 0.1%–17.2%]. The median PFS was 7.6 weeks (two-sided 95% CI, 6.9–26.7). Treatment was well tolerated. Grade 3 treatment-related adverse events occurred in 23% ( n = 7) of patients. In paired pre- and post-treatment tumor samples, no association was found between treatment and PD-L1 or IDO1 tumor expression or IDO-pathway–related gene expression by RNA sequencing. No significant changes in serum tryptophan or kynurenine levels were observed after baseline. Conclusions: Combination epacadostat and pembrolizumab was well tolerated and showed limited antitumor activity in sarcoma. Correlative analyses suggested that inadequate IDO1 inhibition was achieved.

Year:

2025

Alterations in the tumor suppressor ATRX are recurrently observed in mesenchymal neoplasms. ATRX has multiple epigenetic functions including heterochromatin formation and maintenance and regulation of transcription through modulation of chromatin accessibility. Here, we show in murine mesenchymal progenitor cells (MPCs) that Atrx deficiency aberrantly activated mesenchymal differentiation programs. This includes adipogenic pathways where ATRX loss induced expression of adipogenic transcription factors and enhanced adipogenic differentiation in response to differentiation stimuli. These changes are linked to loss of heterochromatin near mesenchymal lineage genes together with increased chromatin accessibility and gains of active chromatin marks. We additionally observed depletion of H3K9me3 at transposable elements, which are derepressed including near mesenchymal genes where they could serve as regulatory elements. Finally, we demonstrated that loss of ATRX in a mesenchymal malignancy, undifferentiated pleomorphic sarcoma, results in similar epigenetic disruption and de-repression of transposable elements. Together, our results reveal a role for ATRX in maintaining epigenetic states and transcriptional repression in mesenchymal progenitors and tumor cells and in preventing aberrant differentiation in the progenitor context.

Year:

2024

Purpose: Epacadostat, an indole 2,3 dioxygenase 1 (IDO1) inhibitor proposed to shift the tumor microenvironment toward an immune-stimulated state, showed early promise in melanoma but has not been studied in sarcoma. This study combined epacadostat with pembrolizumab, which has modest activity in select sarcoma subtypes. Experimental Design: This phase 2 study enrolled patients with advanced sarcoma into five cohorts including i) undifferentiated pleomorphic sarcoma (UPS)/myxofibrosarcoma, ii) liposarcoma (LPS), iii) leiomyosarcoma (LMS), iv) vascular sarcoma, including angiosarcoma and epithelioid hemangioendothelioma (EHE), and v) other subtypes. Patients received epacadostat 100 mg twice daily plus pembrolizumab at 200 mg/dose every 3 weeks. The primary endpoint was best objective response rate (ORR), defined as complete response (CR) and partial response (PR), at 24 weeks by Response Evaluation Criteria In Solid Tumors (RECIST v.1.1). Results: Thirty patients were enrolled (60% male; median age 54 years [range, 24–78]). The best ORR at 24 weeks was 3.3% (PR, n=1 [leiomyosarcoma]; two-sided 95% CI, 0.1%–17.2%). The median PFS was 7.6 weeks (two-sided 95% CI: 6.9–26.7). Treatment was well tolerated. Grade 3 treatment-related adverse events occurred in 23% (n=7) of patients. In paired pre- and post-treatment tumor samples, no association was found between treatment and PD-L1 or IDO1 tumor expression or IDO-pathway–related gene expression by RNA sequencing. No significant changes in serum tryptophan or kynurenine levels were observed after baseline. Conclusions: Combination epacadostat and pembrolizumab was well tolerated and showed limited antitumor activity in sarcoma. Correlative analyses suggested that inadequate IDO1 inhibition was achieved.

Year:

2024

Collaborators (14)

Julia Glade Bender

Vice Chair for Clinical Research

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Mark A. Dickson

-

UNITED STATES
View details

John Skaugen

Assistant Professor of Pathology

University of Pittsburgh School of Medicine

UNITED STATES
View details

Samuel Singer

Vincent Astor Chair of Clinical Research

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Gerald Behr

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Sam S. Yoon

-

UNITED STATES
View details

Andrew Kung

Chair

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Alex Kentsis

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Robert G. Maki

Professor, Member

-

UNITED STATES
View details

Jason Chan

Cedars-Sinai Medical Center

UNITED STATES
View details

Ivy John

-

UNITED STATES
View details

Ciara Kelly

-

UNITED STATES
View details

Maedeh Mohebnasab

Assistant Professor

UPMC Presbyterian

UNITED STATES
View details

Edmund Bartlett

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details